Shridhar Bhat, Omonike Olaleye, Kirsten J. Meyer, Wanliang Shi, Ying Zhang, Jun O. Liu, Shridhar Bhat, Omonike Olaleye, Kirsten J. Meyer, Wanliang Shi, Ying Zhang, Jun O. Liu
文献索引：Bioorg. Med. Chem. 20(14) , 4507-13, (2012)
全文：HTML全文
Our previous target validation studies established that inhibition of methionine aminopeptidases (MtMetAP, type 1a and 1c) from Mycobacterium tuberculosis (Mtb) is an effective approach to suppress Mtb growth in culture. A novel class of MtMetAP1c inhibitors comprising of N'-hydroxy-N-(4H,5H-naphtho[1,2-d]thiazol-2-yl)methanimidamide (4c) was uncovered through a high-throughput screen (HTS). A systematic structure-activity relationship study (SAR) yielded variants of the hit, 4b, 4h, and 4k, bearing modified A- and B-rings as potent inhibitors of both MtMetAPs. Except methanimidamide 4h that showed a moderate Mtb inhibition, a desirable minimum inhibitory concentration (MIC) was not obtained with the current set of MtMetAP inhibitors. However, the SAR data generated thus far may prove valuable for further tuning of this class of inhibitors as effective anti-tuberculosis agents.Copyright © 2012 Elsevier Ltd. All rights reserved.
